Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that an oral presentation will be given at the CHEST Annual Meeting 2020 reinforcing the foundational technology behind its noninvasive nasal swab test to identify lung cancer risk in patients with lung nodules. The meeting, hosted by the American College of Chest Physicians, is being held virtually October 18-21, 2020.

“We are on track to introduce our first-of-its-kind noninvasive nasal swab test for early lung cancer diagnosis in the second half of 2021, which we believe is going to transform how lung cancer is evaluated,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “The data being presented at CHEST further confirm our use of ‘field of injury’ technology to detect genomic signals associated with lung cancer – in this case, to distinguish current from former smokers – using patient samples from the nose, compared to the main lung airway. We look forward to unveiling early data regarding our nasal swab test and our expanding lung cancer portfolio at a ‘Research & Development Day’ event before the end of the year.”

Lung cancer is the leading cause of cancer deaths, killing nearly 160,000 Americans each year – more than the next three leading cancers combined. Lung nodules are typically the first sign of lung cancer; however, determining which lung nodules are cancerous and which are benign is often challenging, which can lead to unnecessary invasive procedures or delayed treatment.

The CHEST Annual Meeting will also feature early data suggesting the potential to use radiologic data to further augment genomics in the diagnosis of interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), the disease area addressed by Veracyte’s Envisia^® Genomic Classifier.

The following oral presentation and e-Poster are available to conference registrants as follows:

Title:	Distinguishing current versus former smokers using whole transcriptome RNAseq of bronchial and nasal airway epithelium (oral presentation)
Presenter:	Carla R. Lamb, M.D., Lahey Hospital & Medical Center
Oral Presentation:	Recorded presentation and live Q&A
Timing:	Sunday, Oct. 18, 2020
	1:45 p.m.-2:45 p.m. (Central Time)
Title:	Relationship between Envisia Genomic Classifier (EGC) and an HRCT-derived fibrotic index from data-driven texture analysis (DTA) on 50 ILD patients
Presenter:	Stephen M. Humphries, Ph.D., National Jewish Health
e-Poster:	# P0961
Timing:	Available throughout the conference

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect our development of the nasal swab test for early lung cancer diagnosis. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte’s belief that its nasal swab test for early lung cancer diagnosis provides clinical value that help physicians diagnose lung cancer. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: Veracyte’s ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte’s tests and the applicability of clinical results to actual outcomes Factors that may impact these forward-looking statements can be found in Item 1A – “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 25, 2020 and in our Quarterly Report on Form 10-Q filed with the SEC on July 30, 2020. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and the Veracyte logo are trademarks of Veracyte, Inc.